ATE205092T1 - Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe - Google Patents

Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Info

Publication number: ATE205092T1
Authority: AT; Austria
Prior art keywords: optionally substituted; derivative; highly water; soluble cyclodextrin; group
Prior art date: 1992-01-30

Application number

AT93101237T

Other languages

English (en)

Inventor

Yoshihiro Ohmachi

Yoshihiro Tsugawa

Akihiro Nagai

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-30

Filing date

1993-01-28

Publication date

2001-09-15

1993-01-28 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205092T1 publication Critical patent/ATE205092T1/de

Links

HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 6
238000004519 manufacturing process Methods 0.000 title abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 4
150000002284 fumagillol derivatives Chemical class 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
229910052717 sulfur Chemical group 0.000 abstract 2
125000006020 2-methyl-1-propenyl group Chemical group 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001450 anions Chemical class 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003860 storage Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT93101237T 1992-01-30 1993-01-28 Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe ATE205092T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1523692		1992-01-30
JP33202192		1992-12-11

Publications (1)

Publication Number	Publication Date
ATE205092T1 true ATE205092T1 (de)	2001-09-15

Family

ID=26351355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93101237T ATE205092T1 (de)	1992-01-30	1993-01-28	Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Country Status (5)

Country	Link
US (1)	US5536623A (de)
EP (1)	EP0555693B1 (de)
AT (1)	ATE205092T1 (de)
CA (1)	CA2088428A1 (de)
DE (1)	DE69330690T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2210600A1 (en) *	1996-07-17	1998-01-17	Takashi Houkan	Inhibitor of tumor metastasis or recurrence
KR100357541B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	푸마질롤 유도체 및 그 제조방법
AU2001278705A1 (en)	2000-08-10	2002-02-25	Takeda Chemical Industries Ltd.	Pharmaceutical composition
JP4922507B2 (ja) *	2000-08-10	2012-04-25	武田薬品工業株式会社	医薬組成物
KR100451485B1 (ko) *	2002-03-28	2004-10-06	주식회사종근당	푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US8865746B2 (en) *	2008-07-18	2014-10-21	Zafgen, Inc.	Methods of treating an overweight or obese subject
WO2010065877A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Methods of treating an overweight or obese subject
WO2010065883A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Method of treating an overweight or obese subject
EP2486004B1 (de)	2009-10-09	2017-05-03	Zafgen, Inc.	Sulfonverbindungen zur verwendung in der behandlung von adipositas
US8815309B2 (en)	2010-01-08	2014-08-26	Zafgen, Inc.	Methods of treating a subject with benign prostate hyperplasia
AU2011204267B2 (en)	2010-01-08	2015-12-03	Zafgen Corporation	Fumagillol type compounds and methods of making and using same
WO2011127304A2 (en)	2010-04-07	2011-10-13	Zafgen Corporation	Methods of treating an overweight subject
CN103249735B (zh)	2010-07-22	2016-04-06	扎夫根股份有限公司	三环化合物及其制备和使用方法
PH12013500934A1 (en)	2010-11-09	2022-10-24	Zafgen Inc	Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en)	2010-11-29	2012-06-07	Zafgen Corporation	Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
KR20140006888A (ko)	2011-01-26	2014-01-16	자프겐 인크.	테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
CN103534244B (zh)	2011-03-08	2016-10-12	扎夫根股份有限公司	氧杂螺[2.5]辛烷衍生物及类似物
AU2012253759B2 (en)	2011-05-06	2016-01-21	Zafgen Inc.	Tricyclic sulfonamide compounds and methods of making and using same
CA2835261C (en)	2011-05-06	2019-06-04	Zafgen, Inc.	Partially saturated tricyclic compounds and methods of making and using same
BR112013028666A2 (pt)	2011-05-06	2017-08-08	Zafgen Inc	compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2763671A2 (de)	2011-10-03	2014-08-13	Zafgen, Inc.	Verfahren zur behandlung von altersbedingten erkrankungen
JP2015509102A (ja)	2012-01-18	2015-03-26	ザフゲン，インコーポレイテッド	三環式スルホン化合物並びにその作製および使用方法
MX2014008706A (es)	2012-01-18	2015-03-05	Zafgen Inc	Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
US9260419B2 (en)	2012-05-07	2016-02-16	Zafgen, Inc.	Polymorphic salt of a metap-2 inhibitor and methods of making and using same
AU2013259617A1 (en)	2012-05-08	2014-11-27	Zafgen, Inc.	Treating hypothalamic obesity with MetAP2 inhibitors
MX356755B (es)	2012-05-09	2018-06-11	Zafgen Inc	Compuestos de tipo fumagilol y metodos para su elaboración y uso.
JP2015536981A (ja)	2012-11-05	2015-12-24	ザフゲン，インコーポレイテッド	三環式化合物ならびにその製造および使用方法
BR112015010223A2 (pt)	2012-11-05	2017-07-11	Zafgen Inc	compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
NZ707773A (en)	2012-11-05	2019-05-31	Zafgen Inc	Methods of treating liver diseases
CN105228610A (zh)	2013-03-14	2016-01-06	扎夫根股份有限公司	治疗肾疾病和其它病症的方法
CN106432255A (zh)	2015-08-11	2017-02-22	扎夫根公司	烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es)	2015-08-11	2017-10-25	Zafgen Inc	Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN113321753B (zh) *	2021-05-19	2022-08-30	山东滨州智源生物科技有限公司	多元糖基氨基酸基环糊精衍生物、水凝胶的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0764884B2 (ja) *	1986-11-27	1995-07-12	株式会社トクヤマ	シクロデキストリン組成物
EP0325199B1 (de) *	1988-01-19	1993-10-27	Takeda Chemical Industries, Ltd.	Fumagillin als angiostatisches Mittel
DE68906942T3 (de) *	1988-03-29	1999-05-12	University Of Florida, Gainesville, Fla.	Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
US5227372A (en) *	1990-03-07	1993-07-13	Children's Medical Center Corporation	Method for retaining ophthalmological agents in ocular tissues
TW282399B (de) *	1990-05-25	1996-08-01	Takeda Pharm Industry Co Ltd
EP1004318A3 (de) *	1991-06-21	2002-08-07	Takeda Chemical Industries, Ltd.	Zyklodextrin-zusammensetzung

1993
- 1993-01-28 AT AT93101237T patent/ATE205092T1/de active
- 1993-01-28 DE DE69330690T patent/DE69330690T2/de not_active Expired - Fee Related
- 1993-01-28 EP EP93101237A patent/EP0555693B1/de not_active Expired - Lifetime
- 1993-01-29 US US08/011,457 patent/US5536623A/en not_active Expired - Fee Related
- 1993-01-29 CA CA002088428A patent/CA2088428A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69330690T2 (de)	2002-06-20
US5536623A (en)	1996-07-16
CA2088428A1 (en)	1993-07-31
EP0555693B1 (de)	2001-09-05
EP0555693A1 (de)	1993-08-18
DE69330690D1 (de)	2001-10-11

Publication	Publication Date	Title
DE69330690D1 (de)	2001-10-11	Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
DE69124715D1 (de)	1997-03-27	Zyklodextrinkomplex
ATE71090T1 (de)	1992-01-15	Heterocyclische verbindungen und deren herstellung und verwendung.
DE68923274D1 (de)	1995-08-03	Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
JP3673888B2 (ja)	2005-07-20	ポルフィリン類金属錯体の製造方法
ATE145209T1 (de)	1996-11-15	Tri-aza-makrocyclen und verfahren zu ihrer herstellung
ATE138571T1 (de)	1996-06-15	Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
HUP0102599A2 (hu)	2001-11-28	Artemizinin-származékok, eljárás a vegyületek előállítására, és a vegyületeket tartalmazó gyógyszerészeti készítmények
Lydon et al.	1982	Synthesis and characterization of coordinated disulfides. Single-crystal structural analysis of [(en) 2Co (S (SC (CH3) 2COOH) C (CH3) 2COO)](ClO4) 2. cntdot. H2O
Derek	1994	Kinetics of aminolysis of some benzoyl fluorides and benzoic anhydrides in non-hydroxylic solvents
DE69013528D1 (de)	1994-12-01	Eine Perfluoralkylgruppe enthaltende Verbindung.
DE3885115D1 (de)	1993-12-02	Verfahren zur Herstellung von Thiolen.
RO92245A (ro)	1987-07-30	Procedeu pentru prepararea unor derivati de 1,6-naftiridina
DE69019294D1 (de)	1995-06-14	Triazolyl-Hydrazidderivate und Verfahren zu ihrer Herstellung.
KR880001645A (ko)	1988-04-25	치료적으로 유용한 프리스티나마이신의 제조방법
ATE215934T1 (de)	2002-04-15	Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
HU895522D0 (en)	1990-09-28	Process for the preparation of new thienyl-oxy-alkyl-amine derivatives and pharmaceutical compositions containing them
KR890000406A (ko)	1989-03-14	신나모일아미드 유도체, 그들의 제조방법, 그들을 함유하는 제약학적 조성물 및 그들의 사용
Santos et al.	1993	Siderophore analogues. Chelating properties of a new cyclic diazadihydroxamic acid
KR900014305A (ko)	1990-10-23	소염제로서의 나프탈렌메탄아미노 유도체의 용도 및 이를 함유한 약학 조성물
Elliott et al.	1987	Pentaammineruthenium (II/III) imidazole and imidazolate complexes of 2-carboxylatoimidazolate and 2-imidazolecarboxaldehyde
SE9802643D0 (sv)	1998-07-29	2,3-Disubstituerade cyklopentanonderivat, förfarande för framställning av den och medicinsk användning därav
KR870001223A (ko)	1987-03-12	포스페이트 에스테르 유도체의 제조방법
KR910006238A (ko)	1991-04-27	피라즐-3-카르복스아미드
AR008257A1 (es)	1999-12-29	Poliamidas estables a la intemperie y procedimiento para su elaboracion y aplicacion